Branded pharmas revenue model is under siegeand its not just one problem. Its a stack.
In a recent piece from DrugPatentWatch, the argument is blunt: there are multiple brutal problems that are systematically eroding the traditional branded revenue eng…

Generic drug competition isnt won in the labits won in the fine print.
If youve ever wondered how some generic manufacturers seem to arrive at market faster than others, the answer often lives in the FDAs Orange Bookand in the quiet, highly technical w…

Biopharma hiring is broken in a very specific way: we keep treating IP as a legal function instead of an operating system.
If youve ever watched a company scramble to fill rolesIP counsel, patent analysts, portfolio managers, licensing leadsonly to dis…

The generic cliff isnt a cliff at allits a deadline.
For pharma companies, the real race doesnt start when patents expire. It starts years earlier, when the clock is still quiet and the boardroom still has time to pretend the future is optional. Then…

Drug patent thickets are often described like a legal nuisancedense, costly, and slow to unwind. But in practice, theyre a business strategy: a way to extend exclusivity, delay competition, and keep biologic blockbusters printing revenue long after the…

AI Prior Art Search: How to Invalidate Key Drug Patents Before You Pay
If youve ever watched a generic launch get delayedor a settlement quietly reshape an entire product roadmapyou already know the real cost of waiting and seeing. In pharma, time is m…

Most teams look at patents the wrong way.
They read claims like a verdicteither youre free to operate or youre not. But in formulation patents, that mindset is often the fastest path to surprise: a blocking patent that never mattered becomes the head…

Russias VED/SSM lists are often treated like a bureaucratic footnoteuntil you realize they can function like a market calendar. For pharma companies planning launches, generic entry timing isnt just about patent expiry dates; its also about when regula…

Pharma pipelines dont fail because of science. They fail because of patents.
Thats the uncomfortable truth behind most surprise development delays: not the biology, but the legal realitywhat you cant do, when you cant do it, and how long you can keep…

Beyond the ANDA: How the 505(b)(2) Pathway Can Turn Copy Into Competitive Moat
In generic drug land, the default playbook is familiar: file an ANDA, win on price, and let scale do the heavy lifting. But that strategy has a ceilingespecially as regulato…